Press Releases

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

September 10, 2018

The interference proceeding remains terminated without any determination of inventorship on CRISPR/Cas9 genome editing technology or its application to eukaryotic cells University of California/University of Vienna/Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology in all environments that do not interfere with the Broad’s patent claims in this proceeding

CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

June 19, 2018

Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules

Caribou Biosciences Appoints Timothy F. Herpin, Ph.D. as Chief Business Officer

May 3, 2018

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer. In this role, Tim will lead the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities.

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

July 25, 2017

Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team

Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific Officer

July 6, 2017

BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.